A detailed history of Aigen Investment Management, LP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Aigen Investment Management, LP holds 22,885 shares of BMY stock, worth $1.29 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
22,885
Previous 125,708 81.8%
Holding current value
$1.29 Million
Previous $5.22 Million 77.32%
% of portfolio
0.24%
Previous 1.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$39.66 - $51.75 $4.08 Million - $5.32 Million
-102,823 Reduced 81.8%
22,885 $1.18 Million
Q2 2024

Aug 09, 2024

BUY
$40.25 - $52.99 $4.42 Million - $5.82 Million
109,757 Added 688.09%
125,708 $5.22 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $765,328 - $867,734
15,951 New
15,951 $865,000
Q4 2022

Feb 10, 2023

BUY
$68.48 - $81.09 $2.86 Million - $3.39 Million
41,754 New
41,754 $3 Million
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $2.02 Million - $2.43 Million
-32,921 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $1.77 Million - $2.06 Million
32,921 New
32,921 $1.91 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $1.36 Million - $1.59 Million
-22,982 Closed
0 $0
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $116,762 - $127,154
-1,886 Reduced 7.58%
22,982 $1.54 Million
Q1 2021

May 11, 2021

BUY
$59.34 - $66.74 $1.48 Million - $1.66 Million
24,868 New
24,868 $1.57 Million
Q2 2020

Aug 10, 2020

SELL
$54.82 - $64.09 $1.39 Million - $1.63 Million
-25,412 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$46.4 - $67.43 $1.18 Million - $1.71 Million
25,412 New
25,412 $1.42 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.